Research programme: anti-infectives - 4SC Discovery/AiCuris/CRELUX

Drug Profile

Research programme: anti-infectives - 4SC Discovery/AiCuris/CRELUX

Alternative Names: Anti-infectious therapeutics - 4SC Dicovery/AiCuris/CRELUX

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator 4SC Discovery; AiCuris; CRELUX
  • Class Small molecules
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Infections

Most Recent Events

  • 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
  • 04 Nov 2013 Early research in Infections in Germany (unspecified route)
  • 04 Nov 2013 AiCuris, CRELUX and 4SC Discovery form a research collaboration to develop small molecule therapeutics for the treatment of Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top